Is it safe?
Can IOVA take a bad year?
Iovance Biotherapeutics, Inc. holds $312M more cash than debt, and is burning $76M a quarter, about 1.0 years of cover.
$312M
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Altman Z-score
- 0.23
Altman Z-score · distress zone, below 1.8
- Cash runway
- 1.0 years
Cash runway · burning $76M a quarter at the current rate
Details›
- Total debtQ1 2026
- $1.0M
- Cash and short-term investments
- $313M
- Net cash
- $312M
- EBITDA, trailing twelve months
- −$344M
- Operating profit, trailing twelve months
- −$363M
- Debt / equity
- 0.00×
- Annualised volatilitytwo years of daily moves
- 102%
- Worst drawdown on file
- −97%
- Below its 52-week high
- −9.8%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.